
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Alkem Laboratories has confirmed a cyber fraud at its US Enzene unit involving compromised emails and fund transfer. Financial impact is still under investigation, while Alkem Laboratories share price closed 3.18% higher at Rs.5,290.35 on 15 May 2025.
Pharmaceutical major Alkem Laboratories Ltd has reported a cybersecurity incident at the US subsidiary of Enzene Biosciences Ltd, a wholly-owned arm of the company. The breach involved the compromise of official email accounts of select employees, leading to a fraudulent transfer of funds. The financial damage caused by the incident is currently under examination. External cybersecurity experts have been appointed to conduct a detailed investigation into the breach.
Also read: Infosys Expands Strategic Partnership With DNB Bank To Boost Digitisation
Cybersecurity breach occurred at Enzene’s US subsidiary, affecting employee email accounts.
Funds were fraudulently transferred using compromised credentials.
Financial loss is under assessment with third-party experts leading the probe.
Complaints are being filed with US governmental and regulatory bodies.
Alkem Laboratories share price ended 3.18% higher at Rs.5,290.35 on the BSE.
Also read: Bajaj Auto Approves ₹1,199.92 Crore Investment in Netherlands Arm
Despite the breach announcement, the stock of Alkem Laboratories saw a positive uptrend. The market appeared to reward the company’s quick disclosure and transparency. The Alkem Laboratories share price increased by Rs.163.20, or 3.18%, settling at Rs.5,290.35 on 15 May 2025. This reflects a relatively strong investor sentiment even in the face of potential financial setbacks.
Date | Closing Price (Rs.) | Change (Rs.) | Change (%) |
15 May 2025 | 5,290.35 | +163.20 | +3.18% |
14 May 2025 | 5,127.15 | — | — |
Alkem Laboratories stated that the disclosure of the incident was made as part of its commitment to good governance and transparency. Both Enzene and Alkem boards will be briefed once the investigation concludes. Meanwhile, formal complaints are being registered with relevant US authorities. The company has not yet disclosed the exact financial impact, citing the ongoing nature of the inquiry.
As the investigation unfolds, the focus will be on assessing recovery options and reinforcing internal cybersecurity frameworks. The company’s proactive stance is likely to play a crucial role in mitigating long-term operational or reputational risks. Investors will be closely watching for further updates, especially if the financial impact turns out to be material. The Alkem Laboratories share price may continue to reflect investor sentiment based on transparency and responsiveness.
Also read: RVNL Wins ₹115.8 Cr Order from Central Railway for Traction Upgrade
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading